综述

不同临床状况下VA-ECMO在高危经皮冠状动脉介入治疗中的应用进展

  • 邓钰莹 ,
  • 黄修献 ,
  • 王圣
展开
  • 海南省人民医院心血管内科,海口 570311
第一联系人:邓钰莹负责文献检索和文章撰写,黄修献参与文献检索及文中表格制作,王圣负责文章的修改。所有作者均阅读并同意了最终稿件的提交。
邓钰莹,主治医师,硕士;电子信箱:kexuanling@163.com

收稿日期: 2025-06-30

  录用日期: 2025-12-19

  网络出版日期: 2026-01-30

Application of VA-ECMO in high-risk percutaneous coronary interventions under different clinical conditions

  • Deng Yuying ,
  • Huang Xiuxian ,
  • Wang Sheng
Expand
  • Department of Cardiology, Hainan General Hospital (Hainan Medical University Hainan Hospital), Haikou 570311, China
First author contact:Deng Yuying was responsible for literature retrieval and manuscript preparation. Huang Xiuxian contributed to literature retrieval and the development of tables in the manuscript. Wang Sheng was responsible for the critical revision of the manuscript. All authors have read the last version of paper and consented to submission.
Deng Yuying, E-mail: kexuanling@163.com.

Received date: 2025-06-30

  Accepted date: 2025-12-19

  Online published: 2026-01-30

摘要

虽然冠状动脉旁路移植术(coronary artery bypass grafting,CABG)是大部分复杂冠脉病变患者的首选治疗方法,但在某些病例,尤其是急危重症、血流动力学不稳定的情况下,机械循环支持(mechanical circulatory support,MCS)下的经皮冠状动脉介入治疗(percutaneous coronary interventions,PCI)可能是不劣于CABG,甚至更优的方案。目前,基于现实世界的观察结果,主动脉内球囊反搏(intra-aortic balloon pump,IABP)这一临床上最常用的循环辅助方式在指南中的推荐地位已经逐步降低。受限于实际硬件条件,Impella在我国尚未推广使用。静脉-动脉体外膜肺氧合(veno-arterial extracorporeal membrane oxygenation,VA-ECMO)得益于其全面而强有力的心肺替代功能,近几年来在我国的应用逐渐普及。该文主要总结不同临床背景下关于VA-ECMO在高危PCI(high-risk PCI,HR-PCI)中应用的研究,为临床工作提供参考和借鉴。

本文引用格式

邓钰莹 , 黄修献 , 王圣 . 不同临床状况下VA-ECMO在高危经皮冠状动脉介入治疗中的应用进展[J]. 上海交通大学学报(医学版), 2026 , 46(1) : 123 -131 . DOI: 10.3969/j.issn.1674-8115.2026.01.015

Abstract

Although coronary artery bypass grafting (CABG) remains the preferred treatment for most patients with complex coronary artery lesions, percutaneous coronary intervention (PCI) supported by mechanical circulatory support (MCS) may be a non-inferior or even superior alternative in specific cases, particularly in critically ill patients with hemodynamic instability. Recent real-world evidence has led to a downgrade in guideline recommendations for the intra-aortic balloon pump (IABP), which has been the most commonly used circulatory assist device in clinical practice. Due to limited availability, the Impella device has not yet been widely adopted in China. In contrast, veno-arterial extracorporeal membrane oxygenation (VA-ECMO), owing to its comprehensive and robust cardiopulmonary replacement capabilities, has seen an increase in utilization across China in recent years. This article reviews current evidence on the application of VA-ECMO in high-risk PCI (HR-PCI) under various clinical conditions, aiming to provide valuable references for clinical practice.

参考文献

[1] Rihal C S, Naidu S S, Givertz M M, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care (endorsed by the American heart association, the cardiological society of India, and sociedad Latino Americana de cardiologia intervencion; affirmation of value by the Canadian association of interventional cardiology-association canadienne de cardiologie d'intervention)[J]. J Card Fail, 2015, 21(6): 499-518.
[2] Chieffo A, Dudek D, Hassager C, et al. Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices[J]. Eur Heart J Acute Cardiovasc Care, 2021, 10(5): 570-583.
[3] Nishimura T, Hirata Y, Ise T, et al. JCS/JSCVS/JCC/CVIT 2023 guideline focused update on indication and operation of PCPS/ECMO/IMPELLA[J]. Circ J, 2024, 88(6): 1010-1046.
[4] Van Den Buijs D M F, Wilgenhof A, Knaapen P, et al. Prophylactic impella CP versus VA-ECMO in patients undergoing complex high-risk indicated PCI[J]. J Interv Cardiol, 2022, 2022: 8167011.
[5] Wampler D A, Collett L, Manifold C A, et al. Cardiac arrest survival is rare without prehospital return of spontaneous circulation[J]. Prehospital Emerg Care, 2012, 16(4): 451-455.
[6] Drennan I R, Lin S, Sidalak D E, et al. Survival rates in out-of-hospital cardiac arrest patients transported without prehospital return of spontaneous circulation: an observational cohort study[J]. Resuscitation, 2014, 85(11): 1488-1493.
[7] Grunau B, Kime N, Leroux B, et al. Association of intra-arrest transport vs continued on-scene resuscitation with survival to hospital discharge among patients with out-of-hospital cardiac arrest[J]. JAMA, 2020, 324(11): 1058-1067.
[8] Panchal A R, Bartos J A, Cabanas J G, et al. Part 3: Adult basic and advanced life support: 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care[J]. Circulation, 2020, 142(16_suppl_2): S366-S468.
[9] Lott C, Truhlá? A, Alfonzo A, et al. European Resuscitation Council Guidelines 2021: cardiac arrest in special circumstances[J]. Resuscitation, 2021, 161: 152-219.
[10] Haneya A, Philipp A, Diez C, et al. A 5-year experience with cardiopulmonary resuscitation using extracorporeal life support in non-postcardiotomy patients with cardiac arrest[J]. Resuscitation, 2012, 83(11): 1331-1337.
[11] Chung S Y, Sheu J J, Lin Y J, et al. Outcome of patients with profound cardiogenic shock after cardiopulmonary resuscitation and prompt extracorporeal membrane oxygenation support: a single-center observational study [J]. Circ J, 2012, 76(6): 1385-1392.
[12] Bougouin W, Dumas F, Lamhaut L, et al. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study[J]. Eur Heart J, 2020, 41(21): 1961-1971.
[13] Rob D, Smalcova J, Smid O, et al. Extracorporeal versus conventional cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest: a secondary analysis of the Prague OHCA trial[J]. Crit Care, 2022, 26(1): 330.
[14] Chen Y S, Lin J W, Yu H Y, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis[J]. Lancet, 2008, 372(9638): 554-561.
[15] Maekawa K, Tanno K, Hase M, et al. Extracorporeal cardiopulmonary resuscitation for patients with out-of-hospital cardiac arrest of cardiac origin: a propensity-matched study and predictor analysis[J]. Crit Care Med, 2013, 41(5): 1186-1196.
[16] Sakamoto T, Morimura N, Nagao K, et al. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest: a prospective observational study[J]. Resuscitation, 2014, 85(6): 762-768.
[17] Bartos J A, Grunau B, Carlson C, et al. Improved survival with extracorporeal cardiopulmonary resuscitation despite progressive metabolic derangement associated with prolonged resuscitation[J]. Circulation, 2020, 141(11): 877-886.
[18] Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial[J]. Lancet, 2020, 396(10265): 1807-1816.
[19] Belohlavek J, Smalcova J, Rob D, et al. Effect of intra-arrest transport, extracorporeal cardiopulmonary resuscitation, and immediate invasive assessment and treatment on functional neurologic outcome in refractory out-of-hospital cardiac arrest: a randomized clinical trial[J]. JAMA, 2022, 327(8): 737-747.
[20] Grunau B, Reynolds J, Scheuermeyer F, et al. Relationship between time-to-ROSC and survival in out-of-hospital cardiac arrest ECPR candidates: when is the best time to consider transport to hospital?[J]. Prehospital Emerg Care, 2016, 20(5): 615-622.
[21] Jeger R V, Radovanovic D, Hunziker P R, et al. Ten-year trends in the incidence and treatment of cardiogenic shock[J]. Ann Intern Med, 2008, 149(9): 618-626.
[22] Wayangankar S A, Bangalore S, Mccoy L A, et al. Temporal trends and outcomes of patients undergoing percutaneous coronary interventions for cardiogenic shock in the setting of acute myocardial infarction: a report from the CathPCI REGISTRY[J]. JACC Cardiovasc Interv, 2016, 9(4): 341-351.
[23] Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock[J]. N Engl J Med, 2017, 377(25): 2419-2432.
[24] O′Gara P T, Kushner F G, Ascheim D D, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2013, 127(4): e362-e425.
[25] Neumann F J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. EuroIntervention, 2019, 14(14): 1435-1534.
[26] Thiele H, Zeymer U, Neumann F J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK Ⅱ): final 12 month results of a randomised, open-label trial[J]. Lancet, 2013, 382(9905): 1638-1645.
[27] Thiele H, Zeymer U, Neumann F J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock[J]. N Engl J Med, 2012, 367(14): 1287-1296.
[28] Sheu J J, Tsai T H, Lee F Y, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock[J]. Crit Care Med, 2010, 38(9): 1810-1817.
[29] Tsao N W, Shih C M, Yeh J S, et al. Extracorporeal membrane oxygenation-assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock[J]. J Crit Care, 2012, 27(5): 530.e1-530.e11.
[30] Chung E S, Lim C, Lee H Y, et al. Results of extracorporeal membrane oxygenation (ECMO) support before coronary reperfusion in cardiogenic shock with acute myocardial infarction[J]. Korean J Thorac Cardiovasc Surg, 2011, 44(4): 273-278.
[31] Kim H, Lim S H, Hong J, et al. Efficacy of veno-arterial extracorporeal membrane oxygenation in acute myocardial infarction with cardiogenic shock[J]. Resuscitation, 2012, 83(8): 971-975.
[32] Wu M-Y, Tseng Y H, Chang Y S, et al. Using extracorporeal membrane oxygenation to rescue acute myocardial infarction with cardiopulmonary collapse: the impact of early coronary revascularization[J]. Resuscitation, 2013, 84(7): 940-945.
[33] Chung S Y, Tong M S, Sheu J J, et al. Short-term and long-term prognostic outcomes of patients with ST-segment elevation myocardial infarction complicated by profound cardiogenic shock undergoing early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention[J]. Int J Cardiol, 2016, 223: 412-417.
[34] Sakamoto S, Taniguchi N, Nakajima S, et al. Extracorporeal life support for cardiogenic shock or cardiac arrest due to acute coronary syndrome[J]. Ann Thorac Surg, 2012, 94(1): 1-7.
[35] Lackermair K, Brunner S, Orban M, et al. Outcome of patients treated with extracorporeal life support in cardiogenic shock complicating acute myocardial infarction: 1-year result from the ECLS-Shock study[J]. Clin Res Cardiol, 2021, 110(9): 1412-1420.
[36] Banning A S, Sabaté M, Orban M, et al. Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial[J]. EuroIntervention, 2023, 19(6): 482-492.
[37] Huang C C, Hsu J C, Wu Y W, et al. Implementation of extracorporeal membrane oxygenation before primary percutaneous coronary intervention may improve the survival of patients with ST-segment elevation myocardial infarction and refractory cardiogenic shock[J]. Int J Cardiol, 2018, 269: 45-50.
[38] Choi K H, Yang J H, Hong D, et al. Optimal timing of venoarterial-extracorporeal membrane oxygenation in acute myocardial infarction patients suffering from refractory cardiogenic shock[J]. Circ J, 2020, 84(9): 1502-1510.
[39] Kim M C, Ahn Y, Cho K H, et al. Benefit of extracorporeal membrane oxygenation before revascularization in patients with acute myocardial infarction complicated by profound cardiogenic shock after resuscitated cardiac arrest[J]. Korean Circ J, 2021, 51(6): 533-544.
[40] Shaukat A, Hryniewicz-Czeneszew K, Sun B, et al. Outcomes of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: a single-center experience and review of the literature[J]. J Invasive Cardiol, 2018, 30(12): 456-460.
[41] Tomasello S D, Boukhris M, Ganyukov V, et al. Outcome of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions: a single-center experience[J]. Heart Lung, 2015, 44(4): 309-313.
[42] Van Den Brink F S, Meijers T A, Hofma S H, et al. Prophylactic veno-arterial extracorporeal membrane oxygenation in patients undergoing high-risk percutaneous coronary intervention[J]. Neth Heart J, 2020, 28(3): 139-144.
[43] Griffioen A M, Van Den Oord S C H, Van Wely M H, et al. Short-term outcomes of elective high-risk PCI with extracorporeal membrane oxygenation support: a single-centre registry[J]. J Interv Cardiol, 2022, 2022: 7245384.
[44] Perera D, Stables R, Clayton T, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention[J]. Circulation, 2013, 127(2): 207-212.
[45] Patel M R, Smalling R W, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial[J]. JAMA, 2011, 306(12): 1329-1337.
[46] Stone G W, Marsalese D, Brodie B R, et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty[J]. J Am Coll Cardiol, 1997, 29(7): 1459-1467.
[47] Schweitzer J, Horn P, Voss F, et al. Incidence of acute kidney injury is lower in high-risk patients undergoing percutaneous coronary intervention supported with impella compared to ECMO[J]. J Cardiovasc Transl Res, 2022, 15(2): 239-248.
[48] O′Neill B P, Grines C, Moses J W, et al. Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2021, 98(4): E501-E512.
[49] Tarantini G, Masiero G, Burzotta F, et al. Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization[J]. Catheter Cardiovasc Interv, 2021, 98(2): E222-E234.
[50] Briguori C, Sarais C, Pagnotta P, et al. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty[J]. Am Heart J, 2003, 145(4): 700-707.
[51] Danek B A, Basir M B, O'Neill W W, et al. Mechanical circulatory support in chronic total occlusion percutaneous coronary intervention: insights from a multicenter U.S. registry[J]. J Invasive Cardiol, 2018, 30(3): 81-87.
文章导航

/